Cinnamon has been utilized to remedy a lot of afflictions of humans Literary works illustrate that it possesses numerous biological activities Our research study is intended to recognize the phyto-derived antiviral substances from Cinnamon against COVID-19 main protease enzyme and to understand the in silico molecular basis of its activity In the present study, 48 isolates compounds from Cinnamon retrieved from the PubMed database, are subjected to docking analysis Docking study was performed using Autodock vina and PyRx software Afterwards, admetSAR, as well as DruLiTo servers, were used to investigate drug-likeness prophecy Our study shows that the nine phytochemicals of Cinnamon are very likely against the main protease enzyme of COVID-19 Further MD simulations could identify Tenufolin (TEN) and Pavetannin C1 (PAV) as hit compounds Utilizing contemporary strategies, these phyto-compounds from a natural origin might establish a reliable medication or support lead identification Identified hit compounds can be further taken for in vitro and in vivo studies to examine their effectiveness versus COVID-19

In silico identification of potential inhibitors from Cinnamon against main protease and spike glycoprotein of SARS CoV-2.

Background Steroid treatment is the mainstay of therapy for nasal polyps and rhinosinusitis. Oral steroids have considerable systemic side effects, and nasal sprays do not sufficiently reach the middle meatus, where polyps originate. Nasal drops might be a more useful formula to deliver steroids into the middle meatus. Objective We sought to investigate whether treatment with fluticasone propionate nasal drops (FPNDs) can reduce the need for surgery, as measured by signs and symptoms of nasal polyposis and chronic rhinosinusitis, in patients who are on the waiting list for functional endoscopic sinus surgery (FESS). Methods Fifty-four patients (28 male) with severe nasal polyposis, chronic rhinosinusitis, or both indicated for FESS were included in a 12-week, double-blind, placebo-controlled study. Use of intranasal steroid spray was stopped at least 4 weeks before randomization. Signs and symptoms were recorded before, during, and at the end of the study period. At the end of the study, a computed tomographic scan was performed, and the need for operation was reassessed by using a standardized scoring method. Results FESS was no longer required in 13 of 27 patients treated with FPNDs versus 6 of 27 in the placebo group (P Conclusion Treatment with FPNDs in patients indicated for FESS can reduce the need for surgery.

Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery

Internal medicine clinical research of traditional Chinese medicine has a long history in our country,in the later development in the process of gradually formed a complete medical system. The development of modern medicine of traditional Chinese medicine clinical research challenges are put forward. This article through to the status quo of internal medicine of traditional Chinese medicine clinical research is analyzed,and puts forward the train of thought and method,the internal medicine of traditional Chinese medicine research work is of great significance to our country.

Internal Medicine of Traditional Chinese Medicine Clinical Research Present Situation and the Solution

The 2019 novel coronavirus disease (COVID-19) was first detected in Wuhan, Hubei Province, China, in late 2019. Since then, COVID-19 has spread to more than 200 countries in the world, and a global pandemic has been declared by the World Health Organization (WHO). At present, no vaccines or therapeutic regimens with proven efficacy are available for the management of COVID-19. Hydroxychloroquine/chloroquine, lopinavir/ritonavir, ribavirin, interferons, umifenovir, remdesivir, and interleukin antagonists, such as tocilizumab, have been recommended as potential treatment options in COVID-19. Transplant patients receiving immunosuppressant medications are at the highest risk of severe illness from COVID-19. At the same time, with regard to receiving polypharmacy and immunosuppressants, treatment options should be chosen with more attention in this population. Considering drug-drug interactions and adverse effects of medications used for the treatment of COVID-19, such as QT prolongation, the dose reduction of some immunosuppressants or avoidance is recommended in transplant recipients with COVID-19. Thus, this narrative review describes clinically important considerations about the treatment of COVID-19 and immunosuppressive regimens regarding modifications, side effects, and interactions in adult kidney or liver allograft recipients.

/pdf/coronavirus-disease-2019-covid-19-and-transplantation-4njcwx3qa4.pdf

Coronavirus Disease 2019 (COVID-19) and Transplantation: Pharmacotherapeutic Management of Immunosuppression Regimen

Chronic cough is defined in adults as a cough that lasts for ≥8 weeks. When it proves intractable to standard-of-care treatment, it can be referred to as refractory chronic cough (RCC). Chronic cough is now understood to be a condition of neural dysregulation. Chronic cough and RCC result in a serious, often unrecognized, disease burden, which forms the focus of the current review. The estimated global prevalence of chronic cough is 2–18%. Patients with chronic cough and RCC report many physical and psychological effects, which impair their quality of life. Chronic cough also has a significant economic burden for the patient and healthcare systems. RCC diagnosis and treatment are often delayed for many years as potential treatable triggers must be excluded first and a stepwise empirical therapeutic regimen is recommended. Evidence supporting most currently recommended treatments is limited. Many treatments do not address the underlying pathology, are used off-label, have limited efficacy and produce significant side-effects. There is therefore a significant unmet need for alternative therapies for RCC that target the underlying disease mechanisms. Early clinical data suggest that antagonists of the purinergic P2X3 receptor, an important mediator of RCC, are promising, though more evidence is needed.

Chronic cough: new insights and future prospects

Cough is the most common symptom in respiratory specialist clinics of tertiary hospitals and outpatient clinics of primary health care facilities. In China, patients with chronic cough account for at least one third of all patients referred to respiratory specialist clinics. Chronic cough without significant abnormal chest radiographic findings is often misdiagnosed as chronic bronchitis or chronic pharyngitis. Misdiagnosis of cough results in unnecessary repetitive testing, such as chest radiographs or computed tomography (CT), and widespread abuse of antibiotics or antitussives with little improvement, and potential adverse effects. Chronic cough impair quality of life badly cause severe economic burden in China (1-5).

/pdf/clinical-practice-guidelines-for-diagnosis-and-management-of-14vfn0hu35.pdf

Qiuping Wang

Papers

Clinical Practice Guidelines for Diagnosis and Management of Cough—Chinese Thoracic Society (CTS) Asthma Consortium